Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T C Ho

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2008
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerAnna Maria Storniolo, Mark D Pegram, Beth Overmoyer, et al.
Gynecologic Oncology|February 9, 2016
Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC)Marcus Q Bernardini, Lilian T Gien, Susie Lau, et al.
Gynecologic Oncology|September 10, 2015
Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancersAlon D Altman, Sarah E Ferguson, Eshetu G Atenafu, et al.
Translational Psychiatry|November 12, 2015
Peripheral telomere length and hippocampal volume in adolescents with major depressive disorderE Henje Blom, L K M Han, C G Connolly, et al.
The Lancet. Oncology|April 14, 2018
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoine Italiano, Jean-Charles Soria, Maud Toulmonde, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2025
Dissecting heterogeneity in cortical thickness abnormalities in major depressive disorder: a large-scale ENIGMA MDD normative modelling studyJ M M Bayer, L S van Velzen, E Pozzi, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2008
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerAnna Maria Storniolo, Mark D Pegram, Beth Overmoyer, et al.
Gynecologic Oncology|February 9, 2016
Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC)Marcus Q Bernardini, Lilian T Gien, Susie Lau, et al.
Gynecologic Oncology|September 10, 2015
Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancersAlon D Altman, Sarah E Ferguson, Eshetu G Atenafu, et al.
Translational Psychiatry|November 12, 2015
Peripheral telomere length and hippocampal volume in adolescents with major depressive disorderE Henje Blom, L K M Han, C G Connolly, et al.
The Lancet. Oncology|April 14, 2018
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoine Italiano, Jean-Charles Soria, Maud Toulmonde, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2025
Dissecting heterogeneity in cortical thickness abnormalities in major depressive disorder: a large-scale ENIGMA MDD normative modelling studyJ M M Bayer, L S van Velzen, E Pozzi, et al.
Pageof 7